Merit Medical Systems, Inc. is a strong participant in the transcatheter embolization market with a broad offering of calibrated, hydrophilic spheres including: Embosphere® Microspheres, EmboGold® Microspheres, QuadraSphere® Microspheres, and HepaSphere™ Microspheres. Embosphere Microspheres are indicated for embolization of symptomatic uterine fibroids, hypervascular tumors and arteriovenous malformations. The company is also sponsoring a clinical trial (HiQuality) titled “HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer.”
According to a new report by iData Research, the U.S. peripheral vascular device market in 2011 is valued at over $3.8 billion. The market is expected to grow rapidly to over $7.1 billion by 2018 fueled by sales of many new products and the increased use of transcatheter embolization devices for new indications such as cancer and stroke treatment. “Transcatheter embolization devices, which are used to occlude blood flow within the vasculature, are expected to be the fastest-growing segment in the overall peripheral vascular market,” says Dr. Kamran Zamanian, CEO of iData. “Their uses are going beyond the treatment of aneurysms and other arteriovenous malformations and are being used in the treatment of growths, cancers, and stroke. In particular, sales of particle embolics, which can deliver drug-coated and radiolabeled beads for targeted drug delivery and radiation therapy, are estimated to grow at double-digit rates through 2018.” (Source: http://www.prweb.com/releases/2011/11/prweb8997564.html)
Merit Medical Systems, Inc. is ideally situated to capture some of the market growth resulting from the expansion of transcather embolization procedures.
Merit Medical Systems, Inc.